Study on the sensitivity of leukemic cells to arsenic trioxide enhanced by targeted suppression of mIRNA-21.
- Author:
Yu-min LI
1
;
Jing-yi GU
;
Xue-jiao ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents; pharmacology; Apoptosis Regulatory Proteins; metabolism; Arsenicals; pharmacology; Gene Expression Regulation, Leukemic; Humans; K562 Cells; MicroRNAs; drug effects; Oligonucleotides, Antisense; pharmacology; Oxides; pharmacology; RNA-Binding Proteins; metabolism; Transfection
- From: Chinese Journal of Integrated Traditional and Western Medicine 2010;30(2):170-173
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of antisense oligonucleotide targeted on miRNA-21 (AMO-miR-21) for enhancing the arsenic trioxide (As2O3) sensitivity of leukemic K562 cells and its possible acting mechanism.
METHODSChemosynthetic AMO-miR-21 was transfected to K562 cells using Lipofectamine TM 2000. The inhibitory effects of As2O3 and AMO-miR-21, used singly or in combining, on cell proliferation were detected by MTT, their inhibition rate and IC50 were calculated. Cell cycle and apoptosis were assessed with PI stain; expression of miRNA-21 in cells was detected quantitatively by real-time PCR, and the potential target gene PDCD, protein expression was detected by immuno-fluorimetry.
RESULTSUsed in combining with AMO-miR-21, the IC50 of As2O3, could be lowered from 2.1 micromol/L to 1.23 micromol/L, and the sensitivity of cells to As2O3 increased to 1.78-fold; with the amount of apoptotic cells increased significantly. Transfection with AMO-miR-21 alone could downregulate the expression of miRNA-21 in cells (P < 0.01), and up-regulate PDCD, protein expression level significantly.
CONCLUSIONSCombined use of AMO-miR-21 and As2O3 could increase the sensitivity of K562 cells to As2O3, which provides a novel potential approach for treatment of leukemia. AMO-miR-21 realizes it anti-tumor action by way of targeted inhibition on miRNA-21, and further up-regulates the expression of anti-tumor gene PDCD4.